GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending GSK’s Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for ...

NHS England has confirmed that it will be the first health system worldwide to roll out the treatment. The drug will be ...

The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest.

A “TROJAN HORSE” therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a ...

England becomes the first country to offer the world’s pioneering 'Trojan horse' blood cancer drug, through NHS, promising ...